Hy2Care® is a ‘spin-off company’ of the Tech Med Centre of the University of Twente, the Netherlands and was founded in 2014. Of the original founders, prof. Marcel Karperien and dr. Sanne Both continue to be involved.
The unique technology of Hy2Care was developed by prof. Marcel Karperien and his team of the Developmental BioEngineering group at the University of Twente. The Injectable Hydrogel technology platform is protected through several patents. Hy2Care’s launching product, the Injectable Patch for Cartilage Repair, is currently being prepared for clinical investigation. Future additional applications are in early-stage R&D phase.
In 2019 Hy2Care received €3.7M Series A funding. It’s current CEO Leo Smit joined, and an additional team expansion was initiated, bringing in also Sanna Severins as Chief Operations Officer and co-director of the company. The goal of the Series A period is to scale up the technology and initiate human trials. Also, a separate product and venture for veterinary applications is under development.
The company continues to use laboratory facilities in Enschede (NL) at the site of the Twente University of Technology, as well as a laboratory and offices at the Brightlands Chemelot Campus in Geleen.